caisehengbanjiancai.png
Home
About Neukio

Corporate Overview

Development History

Corporate Culture

About Founder

Core Team

R&D

R&D Platform

Process Development

News

Press Releases

BD cooperation

BD cooperation

Contact us
中
En
caisehengbanjiancai.png
Cn
  • Home

  • About Neukio

    • Corporate Overview
    • Development History
    • Corporate Culture
    • About Founder
    • Core Team
      • Core Team
  • R&D

    • R&D Platform
    • Process Development
  • News

    • Press Releases
  • BD cooperation

    • BD cooperation
  • Contact us

shouyebanner3-907.jpg banner-shoujishouye3.jpg

Quality-based
Specification-oriented
Patient-centered
Building new future in cell therapy

shouyebanner2-287.jpg banner-shoujishouye2.jpg

Neukio Biotherapeutics on a New Mission

shouyebanner1-454.jpg banner-shoujishouye1.jpg

Let Cell Therapies Eradicate Cancer Cells

See More

shouyebanner3-907.jpg banner-shoujishouye3.jpg

Quality-based
Specification-oriented
Patient-centered
Building new future in cell therapy

shouyebanner2-287.jpg banner-shoujishouye2.jpg

Neukio Biotherapeutics on a New Mission

About Neukio

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK and CAR-T axis, through internal discovery and external collaboration, with emphasis on innovative immune cell products.


See More

Solid tumors

indications

Allogenic

Scalability

Solid tumors

indications

Allogenic

Why iPSC-CAR-NK?

1. NK cells can be universal and readily available (allogeneic use)

2. NK cells can be manufactured in scale via iPSC differentiation and banking

3. Engineered NK have potential to eradicate solid tumors

See More

syerxuz-195.svg

Gene Editing

NK Diff. & Exp.

DP

Banking

iPSC Bank

shoujiduannksucai.png

News

See More

yingwentitu.jpg

Press Releases

2024-11-17

China Biotech Industry: Six foreign-invested enterprises gain approval to engage in stem cell research activities

Foreign invested enterprises are gaining greater access to the biotech industry in China.

tupian1.png

Press Releases

2024-09-24

【Reprinted from Han Kun Law Offices】China Pilots Lifting Restrictions on Foreign Investment in Stem Cell, Gene Therapy, and Genetic Diagnosis Sectors in Four Free Trade Zones

Press Releases

undefined

Press Releases

2024-07-19

Neukio Biotherapeutics and Tofflon Life Sciences Successfully Deliver Customized Glass Bioreactors

wangliqunzhaopian.jpg

Press Releases

2024-02-23

Richard Wang: A Seventeen-Year Odyssey of an Overseas PhD Returnee in the Pursuit of Domestic Innovative Drug Development

1.png

Press Releases

2023-09-29

Richard Wang: Perks enjoyed by companies based in the FTZ

About Founder

See More

Richard Liqun Wang Ph. D., MBA.

Founder, Chairman and CEO, Neukio Biotherapeutics


Former positions held: 

-   VP & CTO, Fosun Pharma, and founding CEO, Fosun Kite Biotech

-   COO, Cellular Biomedical Group (CBMG)

-   Head of Operations, GSK R&D Center in China

-   Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China

-   Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA

-   Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA



See More

shangchuan.png

WELCOME ABOARD

Recruitment@neukio.com

See More

baisehengbanjiancai.png

Address

3F, Building 7-5, No. 160 Basheng Road, China (Shanghai) Pilot Free Trade Zone, 200131

INFO

Admin@neukio.com

Partnership

BD@neukio.com

Media

PR@neukio.com

About Neukio
R&D
News
BD cooperation
Contact us

Follow us

code.jpg

WeChat Official Account

All contents Neukio Biotherapeutics Co, Ltd. All right reserved. Shanghai ICP prepared No. 2021033013-1  Powered by Yongsy站长统计

Privacy TermsLegal Declaration Site Map